KRAS and lung cancer: Accumulating evidences support that concurrent genetic alteration of KRAS and LKB1 defines a unique molecular subtype with potent cancer plasticity, exhibiting high metastatic competence, frequent therapeutic resistance and poor clinical prognosis, and thus represents a major challenge for lung cancer therapeutics (Mahoney et al, 2009; Skoulidis et al, 2015).